Balance Sheet Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-24 pm EST			5-day change	1st Jan Change
275.42 ^USD	-0.89%		+1.22%	+5.67%

Jan. 24	Janux Therapeutics Promotes Zachariah McIver to Chief Medical Officer	MT
Jan. 24	Janux Therapeutics, Inc. Promotes Zachariah McIver to Chief Medical Officer	CI

5e636406be3282d1875f4c329be674da.3wIDllJyFFumJulQhTjRPSpT03rDuU8cuqU-_J8LGBo.k21UzGIWWSreaJ4S11v8b18wlhLziAAu--JqsMhedVCoZ27nP0NbHslPuA

Published financial data: AMGEN INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019	2020	2021	2022	2023
Revenues	22.2B	24.24B	24.3B	24.8B	26.91B
Other Revenues, Total	1.16B	1.18B	1.68B	1.52B	1.28B
Total Revenues	23.36B	25.42B	25.98B	26.32B	28.19B
Cost of Goods Sold, Total	4.36B	6.16B	6.45B	6.41B	8.42B
Gross Profit	19.01B	19.26B	19.52B	19.92B	19.78B
Selling General & Admin Expenses, Total	5.15B	5.73B	5.37B	5.41B	6.17B
R&D Expenses	4.12B	4.21B	4.82B	4.43B	4.76B
Other Operating Expenses	19M	-	-	-	690M
Other Operating Expenses, Total	9.28B	9.94B	10.19B	9.85B	11.61B
Operating Income	9.72B	9.33B	9.34B	10.07B	8.16B
Interest Expense, Total	-1.29B	-1.04B	-1.2B	-1.41B	-2.88B
Interest And Investment Income	587M	-	-	-	-
Net Interest Expenses	-702M	-1.04B	-1.2B	-1.41B	-2.88B
Income (Loss) On Equity Invest.	-	-	-	-	-
Currency Exchange Gains (Loss)	110M	323M	-245M	-233M	42M
Other Non Operating Income (Expenses)	-	-324M	978M	-180M	1.13B
EBT, Excl. Unusual Items	9.13B	8.29B	8.87B	8.25B	6.46B
Restructuring Charges	-47M	-	-194M	-	-267M
Merger & Related Restructuring Charges	-	-	-	-	-
Gain (Loss) On Sale Of Investments	56M	33M	-474M	-479M	1.44B
Gain (Loss) On Sale Of Assets	-	-	-	-503M	-
Asset Writedown	-	-	-	-	-
In Process R&D Expenses	-	-	-1.5B	-	-
Legal Settlements	-	-189M	-	-	-
Other Unusual Items	-	-	-	78M	225M
EBT, Incl. Unusual Items	9.14B	8.13B	6.7B	7.35B	7.86B
Income Tax Expense	1.3B	869M	808M	794M	1.14B
Earnings From Continuing Operations	7.84B	7.26B	5.89B	6.55B	6.72B
Net Income to Company	7.84B	7.26B	5.89B	6.55B	6.72B
Net Income - (IS)	7.84B	7.26B	5.89B	6.55B	6.72B
Net Income to Common Incl Extra Items	7.84B	7.26B	5.89B	6.55B	6.72B
Net Income to Common Excl. Extra Items	7.84B	7.26B	5.89B	6.55B	6.72B
Per Share Items
Net EPS - Basic	12.96	12.4	10.34	12.18	12.56
Basic EPS - Continuing Operations	12.96	12.4	10.34	12.18	12.56
Basic Weighted Average Shares Outstanding	605M	586M	570M	538M	535M
Net EPS - Diluted	12.88	12.31	10.28	12.11	12.49
Diluted EPS - Continuing Operations	12.88	12.31	10.28	12.11	12.49
Diluted Weighted Average Shares Outstanding	609M	590M	573M	541M	538M
Normalized Basic EPS	9.43	8.84	9.73	9.58	7.55
Normalized Diluted EPS	9.37	8.78	9.68	9.53	7.5
Dividend Per Share	5.8	6.4	7.04	7.76	8.52
Payout Ratio	44.75	51.69	68.1	64.04	67.83
American Depositary Receipts Ratio (ADR)	0.04	0.04	0.04	0.04	0.04
Supplemental Items
EBITDA	11.76B	12.77B	12.58B	13.49B	12.24B
EBITA	11.12B	12.13B	11.94B	12.67B	11.36B
EBIT	9.72B	9.33B	9.34B	10.07B	8.16B
EBITDAR	11.93B	12.96B	12.78B	13.67B	12.42B
Total Revenues (As Reported)	23.36B	25.42B	25.98B	26.32B	28.19B
Effective Tax Rate - (Ratio)	14.18	10.68	12.06	10.81	14.49
Current Domestic Taxes	1.32B	955M	883M	1.76B	1.57B
Current Foreign Taxes	277M	277M	359M	304M	786M
Total Current Taxes	1.6B	1.23B	1.24B	2.07B	2.35B
Deferred Domestic Taxes	-298M	-312M	-317M	-1.21B	-1.15B
Deferred Foreign Taxes	-6M	-51M	-117M	-63M	-66M
Total Deferred Taxes	-304M	-363M	-434M	-1.28B	-1.22B
Normalized Net Income	5.71B	5.18B	5.55B	5.16B	4.04B
Interest Capitalized	-	-	-	-	-
Interest on Long-Term Debt	1.29B	1.26B	-	-	-
Supplemental Operating Expense Items
Advertising Expense	789M	962M	843M	841M	647M
Selling and Marketing Expenses	789M	962M	843M	841M	647M
Research And Development Expense From Footnotes	4.12B	4.21B	6.32B	4.43B	4.78B
Net Rental Expense, Total	171M	189M	199M	186M	180M
Imputed Operating Lease Interest Expense	54.8M	49.14M	56.53M	56.84M	78.81M
Imputed Operating Lease Depreciation	116M	140M	142M	129M	101M
Stock-Based Comp., Other (Total)	308M	330M	341M	401M	473M
Total Stock-Based Compensation	308M	330M	341M	401M	473M

Fiscal Period: December	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	6.04B	6.27B	7.99B	7.63B	10.94B
Short Term Investments	2.87B	4.38B	48M	1.68B	-
Total Cash And Short Term Investments	8.91B	10.65B	8.04B	9.3B	10.94B
Accounts Receivable, Total	4.06B	4.52B	4.9B	5.56B	7.27B
Other Receivables	595M	799M	944M	829M	674M
Total Receivables	4.65B	5.32B	5.84B	6.39B	7.94B
Inventory	3.58B	3.89B	4.09B	4.93B	9.52B
Prepaid Expenses	939M	1.16B	1.22B	1.2B	1.65B
Other Current Assets, Total	354M	124M	200M	355M	281M
Total Current Assets	18.44B	21.14B	19.38B	22.19B	30.33B
Gross Property Plant And Equipment	13.75B	14.27B	14.55B	15.29B	16.4B
Accumulated Depreciation	-8.36B	-8.98B	-8.8B	-9.28B	-9.81B
Net Property Plant And Equipment	5.4B	5.3B	5.75B	6.01B	6.59B
Long-term Investments	799M	1.18B	4.5B	3.16B	4.45B
Goodwill	14.7B	14.69B	14.89B	15.53B	18.63B
Other Intangibles, Total	19.41B	16.59B	15.18B	16.08B	32.64B
Other Long-Term Assets, Total	955M	4.06B	1.46B	2.16B	4.51B
Total Assets	59.71B	62.95B	61.16B	65.12B	97.15B
Liabilities
Accounts Payable, Total	1.37B	1.42B	1.37B	1.57B	1.59B
Accrued Expenses, Total	6.86B	7.67B	8.26B	9.49B	12.37B
Current Portion of Long-Term Debt	2.95B	91M	87M	1.59B	1.44B
Current Portion of Leases	140M	153M	145M	156M	119M
Current Income Taxes Payable	-	828M	701M	1.2B	1.66B
Other Current Liabilities	1.51B	1.49B	1.62B	1.68B	1.2B
Total Current Liabilities	12.84B	11.65B	12.18B	15.69B	18.39B
Long-Term Debt	26.95B	32.9B	33.22B	37.35B	63.17B
Long-Term Leases	388M	306M	525M	539M	691M
Deferred Tax Liability Non Current	606M	-	-	-	2.35B
Other Non Current Liabilities	9.26B	8.68B	8.53B	7.88B	6.32B
Total Liabilities	50.03B	53.54B	54.46B	61.46B	90.92B
Common Stock, Total	31.53B	31.8B	32.1B	32.51B	33.07B
Retained Earnings	-21.33B	-21.41B	-24.6B	-28.62B	-26.55B
Comprehensive Income and Other	-528M	-985M	-796M	-231M	-289M
Total Common Equity	9.67B	9.41B	6.7B	3.66B	6.23B
Total Equity	9.67B	9.41B	6.7B	3.66B	6.23B
Total Liabilities And Equity	59.71B	62.95B	61.16B	65.12B	97.15B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	590M	578M	557M	534M	536M
ECS Total Common Shares Outstanding	591M	578M	558M	534M	535M
Book Value / Share	16.36	16.27	12	6.86	11.64
Tangible Book Value	-24.44B	-21.87B	-23.37B	-27.95B	-45.04B
Tangible Book Value Per Share	-41.33	-37.81	-41.86	-52.34	-84.12
Total Debt	30.43B	33.44B	33.98B	39.64B	65.42B
Net Debt	21.52B	22.8B	25.94B	30.34B	54.48B
Debt Equivalent Oper. Leases	1.37B	1.51B	1.59B	1.49B	1.44B
Equity Method Investments, Total	320M	496M	3.63B	2.45B	3.65B
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	358M	486M	647M	828M	993M
Inventories - Work In Process, Total	2.23B	2.44B	2.37B	3.1B	5.75B
Inventories - Finished Goods, Total	999M	970M	1.07B	1B	2.78B
Land - (BS)	263M	259M	279M	292M	339M
Buildings, Total	3.76B	3.86B	4.03B	4.2B	4.51B
Machinery, Total	3.89B	6.53B	6.68B	6.86B	7.09B
Full Time Employees	23.4K	24.3K	24.2K	25.2K	26.7K
Accumulated Allowance for Doubtful Accounts (Supple)	26M	32M	26M	22M	28M

Fiscal Period: December	2019	2020	2021	2022	2023
Net Income	7.84B	7.26B	5.89B	6.55B	6.72B
Depreciation & Amortization - CF	635M	640M	644M	817M	871M
Amortization of Goodwill and Intangible Assets - (CF)	1.4B	2.8B	2.6B	2.6B	3.2B
Depreciation & Amortization, Total	2.04B	3.44B	3.24B	3.42B	4.07B
(Gain) Loss From Sale Of Asset	-	-	-	567M	-
(Gain) Loss on Sale of Investments - (CF)	-	-	-	891M	-1.55B
Asset Writedown & Restructuring Costs	-	-	1.5B	-	-
Stock-Based Compensation (CF)	308M	330M	341M	401M	431M
Other Operating Activities, Total	-304M	-321M	-528M	-1.37B	-710M
Change In Accounts Receivable	-504M	-427M	-429M	-746M	-1.02B
Change In Inventories	-66M	-215M	-165M	-742M	491M
Change In Accounts Payable	164M	45M	-69M	154M	-402M
Change In Income Taxes	-731M	-731M	-650M	-418M	-660M
Change in Other Net Operating Assets	406M	1.11B	119M	1.02B	1.1B
Cash from Operations	9.15B	10.5B	9.26B	9.72B	8.47B
Capital Expenditure	-618M	-608M	-880M	-936M	-1.11B
Sale of Property, Plant, and Equipment	-	-	-	-	-
Cash Acquisitions	-13.62B	-	-2.53B	-3.84B	-26.99B
Divestitures	-	-	-	130M	-
Sale (Purchase) of Intangible assets	-	-	-	-	-
Investment in Marketable and Equity Securities, Total	20B	-4.72B	4.18B	-1.39B	1.67B
Other Investing Activities, Total	-52M	-75M	-35M	-12M	225M
Cash from Investing	5.71B	-5.4B	733M	-6.04B	-26.2B
Long-Term Debt Issued, Total	-	8.91B	4.94B	6.92B	27.78B
Total Debt Issued	-	8.91B	4.94B	6.92B	27.78B
Long-Term Debt Repaid, Total	-4.51B	-6.45B	-4.15B	-297M	-2.1B
Total Debt Repaid	-4.51B	-6.45B	-4.15B	-297M	-2.1B
Issuance of Common Stock	-	-	-	-	-
Repurchase of Common Stock	-7.84B	-3.49B	-4.98B	-6.36B	-
Common Dividends Paid	-3.51B	-3.76B	-4.01B	-4.2B	-4.56B
Common & Preferred Stock Dividends Paid	-3.51B	-3.76B	-4.01B	-4.2B	-4.56B
Other Financing Activities, Total	95M	-90M	-78M	-103M	-72M
Cash from Financing	-15.77B	-4.87B	-8.27B	-4.04B	21.05B
Net Change in Cash	-908M	229M	1.72B	-360M	3.32B
Supplemental Items
Cash Interest Paid	1.3B	1.2B	1.2B	1.2B	2.4B
Cash Income Tax Paid (Refund)	1.9B	1.4B	1.9B	2.4B	3.4B
Levered Free Cash Flow	6.45B	9.04B	7.49B	8.75B	3.12B
Unlevered Free Cash Flow	7.26B	9.69B	8.23B	9.63B	4.92B
Change In Net Working Capital	542M	-699M	308M	-455M	3.62B
Net Debt Issued / Repaid	-4.51B	2.46B	795M	6.62B	25.68B

Fiscal Period: December	2019	2020	2021	2022	2023
Profitability
Return on Assets	9.63	9.51	9.4	9.97	6.29
Return on Total Capital	14.04	14.06	13.97	14.99	8.88
Return On Equity %	70.73	76.13	73.16	126.47	135.79
Return on Common Equity	70.73	76.13	73.16	126.47	135.79
Margin Analysis
Gross Profit Margin %	81.35	75.77	75.16	75.66	70.15
SG&A Margin	22.04	22.54	20.66	20.57	21.87
EBITDA Margin %	50.32	50.22	48.43	51.23	43.4
EBITA Margin %	47.6	47.7	45.95	48.13	40.31
EBIT Margin %	41.61	36.69	35.94	38.25	28.96
Income From Continuing Operations Margin %	33.57	28.57	22.68	24.89	23.83
Net Income Margin %	33.57	28.57	22.68	24.89	23.83
Net Avail. For Common Margin %	33.57	28.57	22.68	24.89	23.83
Normalized Net Income Margin	24.42	20.38	21.35	19.59	14.32
Levered Free Cash Flow Margin	27.62	35.57	28.81	33.25	11.07
Unlevered Free Cash Flow Margin	31.07	38.12	31.69	36.58	17.44
Asset Turnover
Asset Turnover	0.37	0.41	0.42	0.42	0.35
Fixed Assets Turnover	4.51	4.75	4.7	4.48	4.48
Receivables Turnover (Average Receivables)	5.81	5.65	5.16	4.74	4.19
Inventory Turnover (Average Inventory)	1.34	1.65	1.62	1.42	1.16
Short Term Liquidity
Current Ratio	1.44	1.81	1.59	1.41	1.65
Quick Ratio	1.06	1.37	1.14	1	1.03
Operating Cash Flow to Current Liabilities	0.71	0.9	0.76	0.62	0.46
Days Sales Outstanding (Average Receivables)	62.77	64.79	70.76	76.96	87.02
Days Outstanding Inventory (Average Inventory)	273.33	222.16	225.62	256.86	313.34
Average Days Payable Outstanding	94.1	78.99	76.52	73.96	44.38
Cash Conversion Cycle (Average Days)	242	207.96	219.86	259.86	355.98
Long Term Solvency
Total Debt/Equity	314.6	355.46	507.15	1.08K	1.05K
Total Debt / Total Capital	75.88	78.04	83.53	91.55	91.3
LT Debt/Equity	282.62	352.86	503.69	1.04K	1.02K
Long-Term Debt / Total Capital	68.17	77.47	82.96	87.51	89.12
Total Liabilities / Total Assets	83.8	85.05	89.05	94.38	93.59
EBIT / Interest Expense	7.54	8.99	7.8	7.16	2.84
EBITDA / Interest Expense	9.25	12.48	10.68	9.72	4.32
(EBITDA - Capex) / Interest Expense	8.77	11.9	9.94	9.06	3.93
Total Debt / EBITDA	2.55	2.58	2.66	2.9	5.27
Net Debt / EBITDA	1.8	1.76	2.03	2.22	4.39
Total Debt / (EBITDA - Capex)	2.69	2.71	2.86